A number of other research analysts have also weighed in on TRVN. Zacks Investment Research lowered Trevena from a buy rating to a hold rating in a report on Wednesday, May 15th. HC Wainwright set a $4.00 price objective on Trevena and gave the stock a buy rating in a report on Monday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $5.38.
Shares of TRVN stock opened at $0.99 on Monday. The business’s fifty day simple moving average is $1.19. Trevena has a 1-year low of $0.38 and a 1-year high of $3.58. The firm has a market capitalization of $88.66 million, a price-to-earnings ratio of -2.36 and a beta of 2.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.58 and a quick ratio of 3.58.
A number of hedge funds have recently made changes to their positions in the stock. Two Sigma Advisers LP grew its holdings in Trevena by 35.3% during the fourth quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 16,400 shares during the period. Alpine Global Management LLC purchased a new stake in Trevena during the first quarter worth $31,000. JPMorgan Chase & Co. boosted its position in Trevena by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock worth $1,147,000 after purchasing an additional 80,437 shares in the last quarter. Geode Capital Management LLC boosted its position in Trevena by 38.9% during the fourth quarter. Geode Capital Management LLC now owns 477,007 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 133,510 shares in the last quarter. Finally, Tibra Equities Europe Ltd purchased a new stake in Trevena during the first quarter worth $283,000. 23.58% of the stock is currently owned by hedge funds and other institutional investors.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
See Also: 52-Week High/Low
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.